New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
04:55 EDTESPR, ESPR, ESPREsperion Therapeutics management to meet with JMP Securities
Meetings to be held in New York on July 29 and in Boston on July 30 hosted by JMP Securities.
News For ESPR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 29, 2015
14:58 EDTESPRViking Global reports 5.9% passive stake in Esperion
Subscribe for More Information
June 25, 2015
10:00 EDTESPROn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:36 EDTESPREsperion initiated with an Overweight at JPMorgan
Subscribe for More Information
June 24, 2015
10:00 EDTESPROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Autoliv (ALV) downgraded to Sell from Neutral at Goldman... Catamaran (CTRX) downgraded to Neutral from Buy at UBS... Citi (C) downgraded to Hold from Buy at Deutsche Bank... Esperion (ESPR) downgraded to Neutral from Outperform at Credit Suisse... Fortinet (FTNT) downgraded to Neutral from Buy at Citi... General Motors (GM) downgraded to Neutral from Buy at Goldman... Goldman Sachs (GS) downgraded to Hold from Buy at Deutsche Bank... IBERIABANK (IBKC) downgraded to Neutral from Outperform at Baird... Independent Bank (INDB) downgraded to Underperform from Neutral at Baird... Inphi (IPHI) downgraded to Market Perform from Outperform at Northland... MoneyGram (MGI) downgraded to Neutral from Outperform at Macquarie... Sensata (ST) downgraded to Hold from Buy at Cross Research... Teradyne (TER) downgraded to Buy from Conviction Buy at Goldman... Alcobra (ADHD) downgraded to Hold from Speculative Buy at WBB Securities.
07:25 EDTESPREsperion risk/reward favorable following pullback, says UBS
Subscribe for More Information
07:01 EDTESPREsperion downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse assumed coverage on Esperion with a Neutral rating from an Outperform rating and lowered its price target to $86 from $130. The analyst would like to see more visibility on the upcoming FDA decision and product labels for PCSK9s, output of End of Phase 2 FDA meeting with the FDA in August, and clarity on the mechanism of action for ETC-1002 before recommending shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use